Last reviewed 2026-04-20 · How we verify

Visipaque

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: NOT FOR INTRATHECAL USE Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrh

Common side effects

• Warmth
• Discomfort
• Pain
• Diarrhea
• Nausea
• Vomiting
• Headache
• Dizziness
• Anxiety
• Agitation
• Nervousness
• Insomnia

Serious adverse events

• Anaphylactic shock
• Acute renal failure
• Myocardial infarction
• Cardiac arrest
• Pulmonary edema
• Cardiac failure
• Convulsions
• Cerebral vascular disorder
• Cortical blindness
• Pancreatitis

Key clinical trials

• Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (NA)
• Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma (NA)
• Intra-discal Steroid Injection for MODIC I Discopathy (PHASE4)
• Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material (PHASE4)
• Effect of Evolocumab on Coronary Atherosclerosis (PHASE3)
• Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes (PHASE1)
• Correlation Between Computer Tomography Angiography and D-Dimer Level for the Diagnosis of Pulmonary Embolism
• Pediatric Risk of Hypothyroidism With Iodinated Contrast Media (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.